Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPM2A | O95278 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27363671 | 0.84 | CYP2A6 (0.50) | CYP2A6DYRK1ACDK9IDO1CNR1 | |
| SCHEMBL826716 | 0.81 | CYP2A6 (0.44) | CYP2A6CNR1AHRHTR1BKDM4E | |
| Ethoxycarbonyl Group SCHEMBL28441815 | 0.79 | CYP2A6 (0.45) | CYP2A6IDO1CNR1SLC6A4HTR1B | |
| Benzofuran SCHEMBL27671125 | 0.74 | MAOB (0.43) | CYP2A6IDO1CNR1MAOBAHR | |
| SCHEMBL2149910 | 0.73 | CYP2A6 (0.54) | CYP2A6DYRK1ACDK9HTR1BKDM4E | |
| SCHEMBL8798702 | 0.73 | CYP2A6 (0.45) | CYP2A6DYRK1ACDK9IDO1AHR | |
| SCHEMBL12319505 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1ACDK9HTR1BKDM4E | |
| SCHEMBL320843 | 0.71 | DYRK1A (0.55) | CYP2A6DYRK1ACDK9HTR1BEPM2A | |
| SCHEMBL6733 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1ACDK9IDO1AHR | |
| SCHEMBL2008439 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1ACDK9HTR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| EP-1838690-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | Devgen N.V. (BE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-12391660-B2 | Heteroaromatic acetamide derivative, and preparation and use thereof | HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-08-19 | — | — | US | disclosed |
| CN-119591881-A | Polyether organic silicon copolymer containing star polyether, and preparation method and application thereof | 江苏美思德化学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | OCEAN UNIVERSITY OF CHINA (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-118496276-A | Organic electroluminescent material and device | 环球展览公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240270777-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024061371-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州威诺森医药科技有限公司 | 2024-03-28 | — | — | WO | disclosed |
| CN-113150003-B | Organic light-emitting compound and organic electroluminescent device | 北京绿人科技有限责任公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4423233-A | ALPHA-HYDROXY CARBOXIMIDATE INTERMEDIATES | PFIZER INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4381308-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-04-26 | — | — | US | disclosed |
| EP-0068563-A2 | Heterocyclic acetic acid compounds and compositions for treating bone diseases | THE PROCTER & GAMBLE COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4332952-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-06-01 | — | — | US | disclosed |
| US-4030926-A | Light-sensitive material containing a dye-forming combination of a heterocyclic compound and a cyclic dihalodicarbonyl compound in a polymeric binder | AGFA-GEVAERT, A.G. (DT) | 1977-06-21 | — | — | US | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3975537-A | SUBSTITUTED BENZOFURANS | SMITH KLINE (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391660-B2 | Heteroaromatic acetamide derivative, and preparation and use thereof | TRPA1, TRPV1, TRPV5 | CYP2A6 237/4885DYRK1A 1583/4885CDK9 3590/4885 |
| US-20240270777-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, AOC2 | CYP2A6 2622/4885DYRK1A 4499/4885CDK9 2613/4885 |
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | CYP2A6 4003/4885DYRK1A 2526/4885CDK9 1895/4885 |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | HDAC3, HDAC1, HDAC11 | CYP2A6 731/4885DYRK1A 967/4885CDK9 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.